Greenwich LifeSciences, Inc. (GLSI)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
GLSI Insider Trading Activity
GLSI Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $3,036,222 | 19 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Patel Snehal | CEO and CFO | 15 | $2.98M | 0 | $0 | $2.98M |
| Thompson Jaye | VP Clinical Reg Affairs | 4 | $55,140 | 0 | $0 | $55,140 |
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 …
Insider Activity of Greenwich LifeSciences, Inc.
Over the last 12 months, insiders at Greenwich LifeSciences, Inc. have bought $3.04M and sold $0 worth of Greenwich LifeSciences, Inc. stock.
On average, over the past 5 years, insiders at Greenwich LifeSciences, Inc. have bought $1.45M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Patel Snehal (CEO and CFO) — $2.98M. Thompson Jaye (VP Clinical Reg Affairs) — $55,140.
The last purchase of 2,500 shares for transaction amount of $31,275 was made by Patel Snehal (CEO and CFO) on 2025‑01‑10.
List of Insider Buy and Sell Transactions, Greenwich LifeSciences, Inc.
| 2025-01-10 | Patel Snehal | CEO and CFO | 2,500 0.0191% | $12.51 | $31,275 | -0.97% | ||
| 2025-01-07 | Patel Snehal | CEO and CFO | 1,800 0.0138% | $13.75 | $24,750 | -10.93% | ||
| 2025-01-06 | Patel Snehal | CEO and CFO | 1,100 0.0084% | $13.31 | $14,641 | -6.14% | ||
| 2025-01-03 | Patel Snehal | CEO and CFO | 3,400 0.0253% | $12.95 | $44,030 | -4.43% | ||
| 2025-01-02 | Patel Snehal | CEO and CFO | 2,000 0.0154% | $11.97 | $23,940 | +5.15% | ||
| 2024-12-31 | Patel Snehal | CEO and CFO | 2,400 0.0181% | $11.36 | $27,264 | +9.62% | ||
| 2024-12-30 | Patel Snehal | CEO and CFO | 3,200 0.0235% | $11.12 | $35,584 | +12.79% | ||
| 2024-11-21 | Thompson Jaye | VP Clinical Reg Affairs | 1,000 0.0077% | $12.91 | $12,910 | -3.86% | ||
| 2024-09-26 | Patel Snehal | CEO and CFO | 1,500 0.0114% | $14.63 | $21,945 | -9.22% | ||
| 2024-08-12 | Thompson Jaye | VP Clinical Reg Affairs | 800 0.0065% | $13.85 | $11,080 | +0.07% | ||
| 2024-08-06 | Patel Snehal | CEO and CFO | 2,000 0.0151% | $13.81 | $27,620 | -5.29% | ||
| 2024-08-05 | Patel Snehal | CEO and CFO | 5,500 0.0424% | $13.18 | $72,490 | +1.28% | ||
| 2024-08-02 | Thompson Jaye | VP Clinical Reg Affairs | 1,000 0.0082% | $15.15 | $15,150 | -6.48% | ||
| 2024-07-23 | Patel Snehal | CEO and CFO | 1,500 0.0115% | $15.89 | $23,835 | -16.02% | ||
| 2024-07-18 | Thompson Jaye | VP Clinical Reg Affairs | 1,000 0.008% | $16.00 | $16,000 | -13.14% | ||
| 2024-06-13 | Patel Snehal | CEO and CFO | 174,825 1.3679% | $14.30 | $2.5M | -8.28% | ||
| 2024-04-01 | Patel Snehal | CEO and CFO | 3,000 0.0234% | $19.08 | $57,240 | -28.20% | ||
| 2024-03-22 | Patel Snehal | CEO and CFO | 2,500 0.0198% | $19.98 | $49,950 | -30.07% | ||
| 2024-03-20 | Patel Snehal | CEO and CFO | 1,500 0.0112% | $17.68 | $26,520 | -25.27% | ||
| 2024-03-05 | Patel Snehal | CEO and CFO | 30,500 0.2372% | $12.49 | $380,945 | +10.18% |
Insider Historical Profitability
| Patel Snehal | CEO and CFO | 5552502 42.2414% | $66.63M | 67 | 0 | +4.05% |
| Thompson Jaye | VP Clinical Reg Affairs | 264148 2.0095% | $3.17M | 21 | 0 | <0.0001% |
| McWilliams David | director | 620301 4.719% | $7.44M | 3 | 0 | <0.0001% |
| Hallock Kenneth | director | 397304 3.0225% | $4.77M | 4 | 0 | <0.0001% |
| Rothe Eric | director | 313226 2.3829% | $3.76M | 1 | 0 |
Historical Insider Profitability vs. Competitors
Greenwich LifeSciences, Inc. (GLSI) | $2,924,567 | 72 | -4.87% | $157.74M |
$64,487,106 | 32 | -22.92% | $140.02M | |
$35,190,048 | 32 | 37.32% | $150.49M | |
$79,019,806 | 27 | 7.24% | $165.26M | |
$6,915,275 | 21 | -32.61% | $158.47M |
GLSI Institutional Investors: Active Positions
| Increased Positions | 22 | +73.33% | 66,924 | +5.93% |
| Decreased Positions | 8 | -26.67% | 24,189 | -2.14% |
| New Positions | 6 | New | 21,526 | New |
| Sold Out Positions | 3 | Sold Out | 10,640 | Sold Out |
| Total Postitions | 44 | +46.67% | 1M | +3.78% |
GLSI Ownership Change vs Market
Institutional Investor Ownership
| Blackrock, Inc. | $4,373.00 | 2.75% | 357,844 | +7,700 | +2.2% | 2024-12-31 |
| Vanguard Group Inc | $3,360.00 | 2.12% | 274,991 | +1,466 | +0.54% | 2024-12-31 |
| Geode Capital Management, Llc | $1,638.00 | 1.03% | 134,071 | +521 | +0.39% | 2024-12-31 |
| Northern Trust Corp | $1,068.00 | 0.67% | 87,423 | +12,923 | +17.35% | 2024-12-31 |
| Credit Agricole S A | $1,063.00 | 0.67% | 87,000 | 0 | 0% | 2024-12-31 |
| State Street Corp | $895.00 | 0.56% | 73,208 | +1,800 | +2.52% | 2024-12-31 |
| Renaissance Technologies Llc | $277.00 | 0.18% | 22,700 | -9,800 | -30.15% | 2024-12-31 |
| Charles Schwab Investment Management Inc | $201.00 | 0.13% | 16,455 | 0 | 0% | 2024-12-31 |
| Goldman Sachs Group Inc | $184.00 | 0.12% | 15,070 | +15,070 | New | 2024-12-31 |
| Morgan Stanley | $168.00 | 0.11% | 13,774 | -3,257 | -19.12% | 2024-12-31 |